United Therapeutic (UTHR) 121.01 $UTHR
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 4.98% Gain
Comtex SmarTrend(R) - Thu Jul 28, 2:49PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $112.73 to a high of $118.98. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $114.12 on volume of 448,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
Watch for United Therapeutics to Potentially Pullback After Gaining 4.98% Yesterday
Comtex SmarTrend(R) - Thu Jul 28, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $112.73 to a high of $118.98. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $114.12 on volume of 448,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
United Therapeutics Corporation Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Jul 28, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2016.
UTHR: 121.01 (+2.02)
Nivalis (NVLS): Can the Stock Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:46PM CDT
Nivalis Therapeutics (NVLS), which is expected to report second-quarter 2016 results on Aug 1, posted a negative surprise of 15.91% last quarter.
VRTX: 97.00 (+0.79), NVLS: 4.68 (-0.10), UTHR: 121.01 (+2.02), BMY: 74.81 (+0.15)
Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:43AM CDT
Alexion Pharmaceuticals (ALXN), which is set to report second-quarter 2016 results on Jul 28, had delivered a negative earnings surprise of 4.40% last quarter.
UTHR: 121.01 (+2.02), ALXN: 128.60 (-1.80), AMGN: 172.03 (+0.75), BMY: 74.81 (+0.15)
Bristol-Myers (BMY): Stock to Beat Earnings Again in Q2
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 10:41AM CDT
Bristol-Myers Squibb (BMY), which is set to report second-quarter 2016 results on Jul 28, reported a positive earnings surprise of 12.12% last quarter.
UTHR: 121.01 (+2.02), AMGN: 172.03 (+0.75), BMY: 74.81 (+0.15), SNY: 42.63 (+0.03)
Celgene (CELG) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 10:28AM CDT
Celgene Corporation (CELG), which is set to report second-quarter 2016 results on Jul 28, reported a positive earnings surprise of 12.38% last quarter.
UTHR: 121.01 (+2.02), AMGN: 172.03 (+0.75), SNY: 42.63 (+0.03), CELG: 112.19 (+0.93)
Coverage Initiated on Select Drug Manufacturers' Stocks
ACCESSWIRE - Fri Jul 15, 8:16AM CDT
LONDON, UK / ACCESSWIRE / July 15, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. See our complete notes on Ionis Pharma at:
UTHR: 121.01 (+2.02), AMRN: 2.65 (+0.26), DEPO: 18.97 (-0.28), IONS: 29.19 (+0.35)
After Yesterday's Decline of 3.10%, United Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 13, 12:57PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $108.40 to a high of $113.44. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $108.50 on volume of 304,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 121.01 (+2.02)
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.80 (+0.19), INVA: 12.87 (+1.17), GWPH: 94.32 (unch), UTHR: 121.01 (+2.02)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.32 (unch), UTHR: 121.01 (+2.02), PFE: 36.89 (+0.22)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 22.30 (-0.83), UTHR: 121.01 (+2.02), AZN: 34.14 (-0.15)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 121.01 (+2.02), AMRN: 2.65 (+0.26), DEPO: 18.97 (-0.28), IONS: 29.19 (+0.35)
United Therapeutics Rises 1.86% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $118.58 to a high of $121.69. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $119.59 on volume of 230,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Wed May 25, 3:38AM CDT
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $116.62 on volume of 639,000 shares, below average daily volume of 888,000. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
UTHR: 121.01 (+2.02)
United Therapeutics Partnering Deals and Alliances 2010 to 2016
PR Newswire - Tue May 24, 3:47PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
UTHR: 121.01 (+2.02)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 3.59% Gain
Comtex SmarTrend(R) - Fri May 13, 2:22PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $108.42 to a high of $113.33. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $112.99 on volume of 253,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
Crosswind PR Issues Correction to May 9 Press Release
PRWeb - Tue May 10, 3:10PM CDT
Crosswind Media & PR issues the following correction to a press release issued May 9, 2016. The press release titled, "United Therapeutics Selects HCB Health as Agency of Record for Remodulin," was printed in error. This is now removed from online news sources and outlets. Crosswind Media & PR takes full responsibility for this error. This was not an error made by our client, HCB Health, nor the fault of PRWeb. Moreover, the press release was not reviewed or approved by United Therapeutics Corporation.
UTHR: 121.01 (+2.02)
3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 17.36 (-0.53), GILD: 79.47 (-1.77), MRK: 58.66 (+0.23), UTHR: 121.01 (+2.02)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 4.98% Gain
Comtex SmarTrend(R) - Thu Jul 28, 2:49PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $112.73 to a high of $118.98. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $114.12 on volume of 448,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
Watch for United Therapeutics to Potentially Pullback After Gaining 4.98% Yesterday
Comtex SmarTrend(R) - Thu Jul 28, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $112.73 to a high of $118.98. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $114.12 on volume of 448,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
United Therapeutics Corporation Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Jul 28, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2016.
UTHR: 121.01 (+2.02)
Nivalis (NVLS): Can the Stock Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:46PM CDT
Nivalis Therapeutics (NVLS), which is expected to report second-quarter 2016 results on Aug 1, posted a negative surprise of 15.91% last quarter.
VRTX: 97.00 (+0.79), NVLS: 4.68 (-0.10), UTHR: 121.01 (+2.02), BMY: 74.81 (+0.15)
Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:43AM CDT
Alexion Pharmaceuticals (ALXN), which is set to report second-quarter 2016 results on Jul 28, had delivered a negative earnings surprise of 4.40% last quarter.
UTHR: 121.01 (+2.02), ALXN: 128.60 (-1.80), AMGN: 172.03 (+0.75), BMY: 74.81 (+0.15)
Bristol-Myers (BMY): Stock to Beat Earnings Again in Q2
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 10:41AM CDT
Bristol-Myers Squibb (BMY), which is set to report second-quarter 2016 results on Jul 28, reported a positive earnings surprise of 12.12% last quarter.
UTHR: 121.01 (+2.02), AMGN: 172.03 (+0.75), BMY: 74.81 (+0.15), SNY: 42.63 (+0.03)
Celgene (CELG) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 10:28AM CDT
Celgene Corporation (CELG), which is set to report second-quarter 2016 results on Jul 28, reported a positive earnings surprise of 12.38% last quarter.
UTHR: 121.01 (+2.02), AMGN: 172.03 (+0.75), SNY: 42.63 (+0.03), CELG: 112.19 (+0.93)
Coverage Initiated on Select Drug Manufacturers' Stocks
ACCESSWIRE - Fri Jul 15, 8:16AM CDT
LONDON, UK / ACCESSWIRE / July 15, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. See our complete notes on Ionis Pharma at:
UTHR: 121.01 (+2.02), AMRN: 2.65 (+0.26), DEPO: 18.97 (-0.28), IONS: 29.19 (+0.35)
After Yesterday's Decline of 3.10%, United Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 13, 12:57PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $108.40 to a high of $113.44. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $108.50 on volume of 304,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 121.01 (+2.02)
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.80 (+0.19), INVA: 12.87 (+1.17), GWPH: 94.32 (unch), UTHR: 121.01 (+2.02)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.32 (unch), UTHR: 121.01 (+2.02), PFE: 36.89 (+0.22)
Valeant (VRX) Loses European Rights to Psoriasis Candidate
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:59AM CDT
Valeant (VRX) announced that its partner AstraZeneca (AZN) has amended the company's license to its pipeline candidate, brodalumab.
VRX: 22.30 (-0.83), UTHR: 121.01 (+2.02), AZN: 34.14 (-0.15)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 121.01 (+2.02), AMRN: 2.65 (+0.26), DEPO: 18.97 (-0.28), IONS: 29.19 (+0.35)
United Therapeutics Rises 1.86% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $118.58 to a high of $121.69. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $119.59 on volume of 230,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Wed May 25, 3:38AM CDT
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $116.62 on volume of 639,000 shares, below average daily volume of 888,000. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
UTHR: 121.01 (+2.02)
United Therapeutics Partnering Deals and Alliances 2010 to 2016
PR Newswire - Tue May 24, 3:47PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
UTHR: 121.01 (+2.02)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 3.59% Gain
Comtex SmarTrend(R) - Fri May 13, 2:22PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $108.42 to a high of $113.33. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $112.99 on volume of 253,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 121.01 (+2.02)
Crosswind PR Issues Correction to May 9 Press Release
PRWeb - Tue May 10, 3:10PM CDT
Crosswind Media & PR issues the following correction to a press release issued May 9, 2016. The press release titled, "United Therapeutics Selects HCB Health as Agency of Record for Remodulin," was printed in error. This is now removed from online news sources and outlets. Crosswind Media & PR takes full responsibility for this error. This was not an error made by our client, HCB Health, nor the fault of PRWeb. Moreover, the press release was not reviewed or approved by United Therapeutics Corporation.
UTHR: 121.01 (+2.02)
3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 17.36 (-0.53), GILD: 79.47 (-1.77), MRK: 58.66 (+0.23), UTHR: 121.01 (+2.02)
